Paxalisib

N/A

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NamePaxalisib
Drug Alias NameGDC-7666RG-7666GDC-0084G-02441729SIM0395
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsPI3-kinase class ISerine/threonine-protein kinase mTOR
Therapy Area/IndicationsBrain metastasesCNS Embryonal TumorSolid tumours +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKazia TherapeuticsSoVarGen Co LtdKazia Therapeutics Ltd +[5] 
Inactive CompaniesDana-Farber Cancer InstituteWeill Medical College of Cornell University
Active IndicationsBrain metastasesCNS Embryonal TumorSolid tumours +[9] 
Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A